Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

419 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease.
Lopez Lopez C, Tariot PN, Caputo A, Langbaum JB, Liu F, Riviere ME, Langlois C, Rouzade-Dominguez ML, Zalesak M, Hendrix S, Thomas RG, Viglietta V, Lenz R, Ryan JM, Graf A, Reiman EM. Lopez Lopez C, et al. Among authors: ryan jm. Alzheimers Dement (N Y). 2019 Jun 12;5:216-227. doi: 10.1016/j.trci.2019.02.005. eCollection 2019. Alzheimers Dement (N Y). 2019. PMID: 31211217 Free PMC article. Review.
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA; CATIE-AD Study Group. Schneider LS, et al. Among authors: ryan jm. N Engl J Med. 2006 Oct 12;355(15):1525-38. doi: 10.1056/NEJMoa061240. N Engl J Med. 2006. PMID: 17035647 Free article. Clinical Trial.
Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease.
Carrillo MC, Brashear HR, Logovinsky V, Ryan JM, Feldman HH, Siemers ER, Abushakra S, Hartley DM, Petersen RC, Khachaturian AS, Sperling RA. Carrillo MC, et al. Among authors: ryan jm. Alzheimers Dement. 2013 Mar;9(2):123-131.e1. doi: 10.1016/j.jalz.2012.12.004. Epub 2013 Feb 12. Alzheimers Dement. 2013. PMID: 23411394 Review.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Active immunotherapy options for Alzheimer's disease.
Winblad B, Graf A, Riviere ME, Andreasen N, Ryan JM. Winblad B, et al. Among authors: ryan jm. Alzheimers Res Ther. 2014 Jan 30;6(1):7. doi: 10.1186/alzrt237. eCollection 2014. Alzheimers Res Ther. 2014. PMID: 24476230 Free PMC article. Review.
419 results